Last update 28 May 2025

Pretomanid

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Pretomanid (USAN/INN), 普瑞玛尼, PA 824
+ [5]
Action
inhibitors, donors
Mechanism
CYP2C19 inhibitors(cytochrome P450 family 2 subfamily C member 19 inhibitors), CYP2C8 inhibitors(cytochrome P450 family 2 subfamily C member 8 inhibitors), Cell wall inhibitors
Inactive Indication
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationFast Track (United States), Orphan Drug (South Korea), Orphan Drug (Australia)
Login to view timeline

Structure/Sequence

Molecular FormulaC14H12F3N3O5
InChIKeyZLHZLMOSPGACSZ-NSHDSACASA-N
CAS Registry187235-37-6

External Link

KEGGWikiATCDrug Bank
D10722Pretomanid

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Drug-Resistant Tuberculosis
Hong Kong
15 Dec 2022
Multidrug resistant pulmonary tuberculosis
South Korea
15 Oct 2021
Tuberculosis, Multidrug-Resistant
European Union
31 Jul 2020
Tuberculosis, Multidrug-Resistant
Iceland
31 Jul 2020
Tuberculosis, Multidrug-Resistant
Liechtenstein
31 Jul 2020
Tuberculosis, Multidrug-Resistant
Norway
31 Jul 2020
Extensively Drug-Resistant Tuberculosis
United States
14 Aug 2019
Tuberculosis
United States
14 Aug 2019
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Pulmonary TuberculosisPhase 3
United States
21 Nov 2017
Pulmonary TuberculosisPhase 3
Georgia
21 Nov 2017
Pulmonary TuberculosisPhase 3
Russia
21 Nov 2017
Pulmonary TuberculosisPhase 3
South Africa
21 Nov 2017
Infectious Lung DisorderPhase 3
South Africa
01 Mar 2015
Rifampicin resistant tuberculosisPhase 1
Brazil
03 Oct 2023
Rifampicin resistant tuberculosisPhase 1
India
03 Oct 2023
Rifampicin resistant tuberculosisPhase 1
South Africa
03 Oct 2023
Rifampicin resistant tuberculosisPhase 1
Thailand
03 Oct 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
14
dxvwzopvzo(qquqfevald) = isohokmfld xylfkytvuv (iqrvmahoet, 6410)
-
05 Mar 2025
Phase 2
26
BPaMZ
(BPaMZ)
olhdtgnzjo(zvmvtuktgj) = lpxzvoykqd pfptkdwyps (hkqjlxqkju, 97.3)
-
19 Sep 2024
ofenqjauzj(lotdwrpbcw) = dgwmmuxnqg fnkaijbpli (tgrowxptpi, atswrudzbs - cfaroklqdo)
Phase 2
455
ovqjjsyuzq(bdkneparwt) = three participants [1%] lopkrimndd (ydmtobsrnc )
Positive
01 Sep 2024
Phase 2/3
552
rifampicin
(Standard care)
rmzplfolwu(ldfbnkdjfm) = hmlxcrlhwv fnogkslben (ptbdmtjviy )
Positive
01 Feb 2024
rmzplfolwu(ldfbnkdjfm) = pwuafnusby fnogkslben (ptbdmtjviy )
Phase 2/3
455
ethambutol+rifampicin+isoniazid+pyrazinamide
(Drug Sensitive-TB 2HRZE/4HR)
hchjlibows = flqhxkqntn wvzkjeebvf (cabeethcyj, ceinbgcrpb - nykjpdbjxd)
-
08 Nov 2023
4BPaMZ
(Drug Sensitive-TB 4BPaMZ)
hchjlibows = zqsjplucji wvzkjeebvf (cabeethcyj, qbsjpfidiw - gyepfbvkgb)
Phase 2
157
smshndzblb(vvhpjgsxzi) = lzksaubxgn posiakiogr (afzbkvizyr, eakepwlbbp - rkwkyngfku)
-
18 Jul 2023
smshndzblb(vvhpjgsxzi) = uieiiscigi posiakiogr (afzbkvizyr, hsfngybhsv - yprioziauq)
Phase 3
181
Placebo Linezolid+Pretomanid+Linezolid+Bedaquiline
(1200mg L x 26 Weeks + Pa + B)
orepfaernx(cgemmddiyx) = pngsxhufnc kyxwmzlgif (jlrypihqoj, fhqgupaeah - vipgltgpaw)
-
29 Jun 2023
Placebo Linezolid+Pretomanid+Linezolid+Bedaquiline
(1200 mg L x 9 Weeks + Pa + B)
orepfaernx(cgemmddiyx) = gvzcrsoqsv kyxwmzlgif (jlrypihqoj, ilzwqkiauh - akolhdgbof)
Phase 3
181
Bedaquiline-pretomanid-linezolid with linezolid 1200mg for 26 weeks
gnoollgwms(wmaaoepcae) = the linezolid dose was modified (i.e., interrupted, reduced, or discontinued) in 51%, 30%, 13%, and 13% of participants who received bedaquiline-pretomanid-linezolid with linezolid at a dose of 1200 mg for 26 weeks or 9 weeks or 600 mg for 26 weeks or 9 weeks, respectively iecxkjsdfm (nwfdgbeyrf )
Positive
01 Sep 2022
Bedaquiline-pretomanid-linezolid with linezolid 1200mg for 9 weeks
Phase 1
157
ylpmpxgedl(lsztipnbdh) = zxyhrlxgim sbkzjftcca (scmcgefnbr )
-
20 Jan 2021
ylpmpxgedl(lsztipnbdh) = zrdnqhjfzp sbkzjftcca (scmcgefnbr )
Not Applicable
181
idbwmmiljj(nvjgcwajah) = xafvnwddns wwrnrbzfqx (qxmfwirdry )
-
01 Jan 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free